157 related articles for article (PubMed ID: 32552908)
1. Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions.
Ahmed ES; Elnour LS; Hassan R; Siddig EE; Chacko ME; Ali ET; Mohamed MA; Munir A; Muneer MS; Mohamed NS; Edris AMM
BMC Res Notes; 2020 Jun; 13(1):295. PubMed ID: 32552908
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators.
Makarewicz R; Zyromska A; Andrusewicz H
Folia Histochem Cytobiol; 2011; 49(3):452-7. PubMed ID: 22038225
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of MST4, STK25 and PDCD10 between benign prostatic hyperplasia and prostate cancer.
Zhang H; Ma X; Peng S; Nan X; Zhao H
Int J Clin Exp Pathol; 2014; 7(11):8105-11. PubMed ID: 25550858
[TBL] [Abstract][Full Text] [Related]
4. Expression of NGF, GDNF and MMP-9 in prostate carcinoma.
Baspinar S; Bircan S; Ciris M; Karahan N; Bozkurt KK
Pathol Res Pract; 2017 May; 213(5):483-489. PubMed ID: 28237042
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
6. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
8. Expression Levels of IL-17A, IL-17F, IL-17RA, and IL-17RC in Prostate Cancer with Taking into Account the Histological Grade according to Gleason Scale in Comparison to Benign Prostatic Hyperplasia: In Search of New Therapeutic Options.
Janiczek M; Szylberg Ł; Antosik P; Kasperska A; Marszałek A
J Immunol Res; 2020; 2020():4910595. PubMed ID: 32537467
[TBL] [Abstract][Full Text] [Related]
9. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
[TBL] [Abstract][Full Text] [Related]
10. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
[TBL] [Abstract][Full Text] [Related]
11. Expression of estrogen receptor-B ( ER-B ) in bengin and malignant prostatic epithelial cells and its correlation with the clinico-pathological features.
Gabal SM; Habib FM; Helmy DO; Ibrahim MF
J Egypt Natl Canc Inst; 2007 Dec; 19(4):239-48. PubMed ID: 19672287
[TBL] [Abstract][Full Text] [Related]
12. Prostasin regulates iNOS and cyclin D1 expression by modulating protease-activated receptor-2 signaling in prostate epithelial cells.
Chen LM; Hatfield ML; Fu YY; Chai KX
Prostate; 2009 Dec; 69(16):1790-801. PubMed ID: 19670249
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 expression in prostate carcinoma.
Pereira RA; Ravinal RC; Costa RS; Lima MS; Tucci S; Muglia VF; Reis RB; Silva GE
Braz J Med Biol Res; 2014 Jun; 47(6):515-21. PubMed ID: 24820071
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
[TBL] [Abstract][Full Text] [Related]
15. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate.
Gupta V; Garg M; Chaudhry M; Singh S; Sen R; Gill M; Sangwaiya A
Prostate Int; 2014; 2(2):90-6. PubMed ID: 25032195
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
17. Comparative Expression of RAGE and SOX2 in Benign and Malignant Prostatic Lesions.
Aboushousha T; Lashen R; Abdelnaser K; Helal N; Moussa M; Omran Z; Eldahshan S; El Ganzoury H
Asian Pac J Cancer Prev; 2019 Feb; 20(2):615-620. PubMed ID: 30806068
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
Ricote M; García-Tuñón I; Bethencourt FR; Fraile B; Paniagua R; Royuela M
Cancer; 2004 Apr; 100(7):1388-96. PubMed ID: 15042672
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study.
Zhang XH; Sakamoto H; Takenaka I
Br J Urol; 1996 Mar; 77(3):441-4. PubMed ID: 8814853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
